An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report looked at people with MASLD (metabolic dysfunction–associated steatotic liver disease, a common form of fatty liver linked to metabolic problems) and compared outcomes for those taking resmetirom versus those taking semaglutide. The headline claim is that, in this real-world analysis, people on resmetirom had fewer Major Adverse Cardiovascular Events (MACE) than people on semaglutide. The story is based on observational data rather than a randomized clinical trial, so it’s an association from routine care, not proof of cause and effect. Resmetirom is a drug designed to target the liver’s metabolism; it’s meant to reduce fat in the liver and improve liver health by acting on thyroid hormone pathways in the liver. Semaglutide is a different kind of medicine that many people know from diabetes and weight-loss treatments (brand names include Ozempic and Wegovy). Semaglutide mimics a gut hormone that lowers blood sugar and reduces appetite. So these are two very different medicines that might be used in overlapping groups of people with metabolic disease. What the research actually shows is an analysis of real-world patient records comparing cardiovascular outcomes between the two groups. The finding reported is a lower rate of MACE — events like heart attack, stroke, or cardiovascular death — in those taking resmetirom compared with those on semaglutide. Important to note: observational studies like this can be influenced by differences between the groups that aren’t fully measured or adjusted for. The snippet doesn’t say how many people were included, how long they were followed, or whether other health differences could explain the result. So the effect is an interesting signal, not definitive proof. Why this could matter is straightforward: people with MASLD are at higher risk for heart disease, and therapies that reduce liver fat might also change cardiovascular risk. If one medication is linked to fewer heart events in real-world practice, clinicians and patients would want to know why and whether that could guide treatment choices. It’s especially relevant for doctors treating patients with overlapping liver disease, obesity, and diabetes who must decide which drugs to prioritize. There are important caveats and risks. Real-world analyses can’t fully remove biases: people prescribed one drug may differ in age, other illnesses, or the reason they were chosen for that drug. Side effects and safety profiles of each drug still matter; semaglutide is well known to cause nausea, gastrointestinal issues, and rare gallbladder problems, while resmetirom’s safety and broader effects depend on ongoing trials and regulatory review. The snippet doesn’t state regulatory status, so don’t assume resmetirom is approved for widespread use in all countries. Until randomized controlled trials directly compare cardiovascular outcomes, this finding should be treated as preliminary. Bottom line: an observational study reports fewer major heart events with resmetirom than with semaglutide in people with MASLD, but the result is an interesting hint rather than proof, and more rigorous research is needed before changing treatment decisions.
Source: HCPLive